"Lilly is committed to supporting initiatives that foster the translation of scientific evidence into clinical practice and improve patient outcomes," said Kara Clinton, Senior Vice President of ...
Eli Lilly (NYSE:LLY) recently announced several significant events, including promising trial results for baricitinib in ...
U.S. drugmakers Johnson & Johnson and Eli Lilly increased spending on security for their top executives in 2024, citing ...
Novo Nordisk is a great pick to buy with the stock near its 52-week low. Vertex Pharmaceuticals is helping patients and ...
Eli Lilly plans to launch its blockbuster diabetes and weight-loss drug in major emerging markets like India, Brazil and ...
Presiding over the upward trajectory of Eli Lilly over the last eight years is paying off nicely for CEO David Ricks. | ...
Eli Lilly (NYSE: LLY) stock defied today's market downturn, rising 2.6% through 11:15 a.m. ET on the back of two positive press releases. In one, Lilly announced plans to acquire the farnesoid X ...
Truist Financial analyst Srikripa Devarakonda maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) today. The company’s shares closed yesterday at $901.80. See what stocks are ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback